OnKure director granted 7,650 stock options

OnKure Therapeutics director R. Michael Carruthers received a new stock option grant.

Rhea-AI Filing Summary

OnKure Therapeutics director R. Michael Carruthers received a new stock option grant. On June 4, 2026, he was granted options covering 7,650 shares of Class A common stock at an exercise price of $4.30 per share.

All 7,650 option shares will vest on the earlier of June 4, 2027 or the day before OnKure’s next annual stockholder meeting, as long as he continues as a service provider through that date. After this grant, he holds options for 7,650 shares directly, with an expiration date of June 3, 2036.

Insider Trade Summary

Grant/Award: 7,650 shares

Grant/Award 1 txn

Insider Carruthers R Michael

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	7,650	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 7,650 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

Key Figures

Options granted: 7,650 options Exercise price: $4.30 per share Underlying shares: 7,650 shares +3 more

6 metrics

Options granted 7,650 options Stock Option (right to buy) granted June 4, 2026

Exercise price $4.30 per share Conversion/exercise price for 7,650 option shares

Underlying shares 7,650 shares Class A Common Stock underlying the options

Options after transaction 7,650 options Total options held following the grant

Vesting date June 4, 2027 (or earlier trigger) Vests earlier of June 4, 2027 or day before next annual meeting

Expiration date June 3, 2036 Option expiration for the 7,650 granted options

Key Terms

Stock Option (right to buy), Class A Common Stock, exercise price, expiration date, +2 more

6 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Class A Common Stock financial

"underlying_security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

exercise price financial

"conversion_or_exercise_price: 4.3000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders"

service provider financial

"subject to the Reporting Person continuing as a service provider through the applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OnKure Therapeutics (OKUR) director R. Michael Carruthers receive in this Form 4?

R. Michael Carruthers received a grant of stock options for 7,650 shares of OnKure Class A common stock. The options are compensation, not an open-market trade, and give him the right to buy shares at a fixed exercise price.

What are the key terms of the 7,650 OnKure (OKUR) stock options granted?

The grant covers 7,650 underlying Class A common shares with an exercise price of $4.30 per share. The options expire on June 3, 2036, giving a long window for potential future exercise if vesting conditions are met.

When do R. Michael Carruthers’s OnKure (OKUR) options vest?

All 7,650 option shares will vest on the earlier of June 4, 2027 or the day before OnKure’s next annual stockholder meeting. Vesting is contingent on Carruthers continuing as a service provider through the applicable vesting date.

Did the OnKure (OKUR) Form 4 show any share sales or purchases by R. Michael Carruthers?

The Form 4 reports only a grant of stock options, classified as an acquisition, with no open-market share purchases or sales. It reflects routine equity-based compensation rather than trading activity in OnKure common stock.

How many OnKure (OKUR) option shares does R. Michael Carruthers hold after this grant?

Following the grant, Carruthers directly holds stock options covering 7,650 underlying shares of Class A common stock. This reflects his total option position shown in the filing, with no additional derivative holdings listed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 06:23 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carruthers R Michael

(Last) (First) (Middle)

C/O ONKURE THEREAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.3	06/04/2026		A		7,650		(1)	06/03/2036	Class A Common Stock	7,650	$0	7,650	D

Explanation of Responses:

1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

	/s/ Rogan Nunn, by power of attorney	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)